Tien Liang BioTech Co (ROCO:4127) ROCE % : 6.08% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Tien Liang BioTech Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tien Liang BioTech Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 6.08%.

Tien Liang BioTech Co ROCE % Historical Data

The historical data trend for Tien Liang BioTech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tien Liang BioTech Co ROCE % Chart

Tien Liang BioTech Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-7.87

-10.99

12.42

13.25

4.10

Tien Liang BioTech Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															4.77	5.34	-0.75	7.02	6.08

Tien Liang BioTech Co ROCE % Calculation

Tien Liang BioTech Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	20.497	/	( ( (676.429 - 185.513)	+	(654.035 - 144.849) )	/ 2 )
	=	20.497	/	( (490.916	+	509.186)	/ 2 )
	=	20.497	/	500.051
	=	4.10 %

Tien Liang BioTech Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	31.172	/	( ( (654.035 - 144.849)	+	(656.435 - 139.553) )	/ 2 )
	=	31.172	/	( ( 509.186	+	516.882 )	/ 2 )
	=	31.172	/	513.034
	=	6.08 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Tien Liang BioTech Co (ROCO:4127) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tien Liang BioTech Co ROCE % Related Terms

Thank you for viewing the detailed overview of Tien Liang BioTech Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tien Liang BioTech Co (ROCO:4127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tien Liang BioTech Co Ltd (ROCO:4127) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Datong Road, 9F, No. 147, Sec. 1, Xizhi District, New Taipei City, TWN

Website

http://www.tlb.com.tw

Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis and hepatic diseases.

Tien Liang BioTech Co (ROCO:4127) Headlines

No Headlines